Pathways to Improving Outcomes in Pediatric/Adolescent Patients with Atopic Dermatitis

Allergists, Dermatologists, Pediatric dermatologists

Activity Information

Credits: 0.5 AMA PRA Category 1 Credit(s)
Launch Date: October 10, 2019
Expiration Date: October 10, 2020


Robert Sidbury, M.D., M.P.H.
Chief, Division of Dermatology
Seattle Children’s Hospital
Professor, Department of Pediatrics
University of Washington School of Medicine
Seattle, WA

Steven R. Feldman, MD, PhD
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, NC


  1. Develop strategies for the co-management of atopic dermatitis (AD) and its associated comorbid conditions     
  2. Identify and manage side effects associated with current AD treatments, including ocular events
  3. Tailor treatment regimens for AD based on current guideline recommendations and patient-specific characteristics     
  4. Facilitate shared decision-making (SDM) for patients with AD through patient engagement and education


This activity was launched on October 10, 2019 and will expire on October 10, 2020.
This activity has been designed to meet the educational needs of allergists, dermatologists, pediatric dermatologists (MD/DOs), and nurse practitioners (NPs), physician assistants (PAs) who manage patients with AD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of credit will be available to print from your user history page.

    Read the learning objectives and faculty disclosures.
    Participate in the activity.
    Complete the post-test and activity evaluation.
    Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
    All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Dr. Feldman has served as a Consultant for Abbvie, Alvotech, Advance Medical, Caremark, Celgene, Galderma Laboratories, L.P., Gerson Lehrman Group, Guidepoint Blobal, Janssen, Kikaku, Leo Pharma Inc., Lilly, Medical Quality Enhancement Corporation, Merck & Co., Inc, Mylan, Novartis Pharmaceuticals, Pfizer Inc., Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, Ortho Dermatology and Xenoport. He has served as a Speaker for Abbvie, Celgene, Janssen, Leo Pharma Inc., Lilly, Novartis Pharmaceuticals, Pfizer Inc., Regeneron, Sanofi, Sun Pharma, Taro, and Ortho Dermatology. He has received grant support from Abbvie, Celgene, Galderma Laboratories, L.P., Janssen, Novartis Pharmaceuticals, Pfizer, Regeneron, Sanofi, and Taro. He is Founder, Stock holder, Chief Technology Officer for Causa Technologies. He has received Royalties form Informa, UpToDate and Xlibris. He is a majority stock owner in Mecial Quality Enhancement.

Dr. Sidbury
Dr. Robert Sidbury has served on an Advisory Board for Pfizer. He has served as an investigator for Regeneron and Brickell. He has served as a Consultant for Micreos.
Other Contributor/Planner Disclosures
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Supporter Acknowledgement
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above